title: Valacyclovir for the management of herpes viral infections.
abstract: The Herpesviridae family (Types 1-8) continues to inflict considerable morbidity and social stigma upon humanity. Once infected with the herpes viruses, especially Types 1-3, they establish permanent residence within our nervous system and reactivate during periods of stress, trauma, and/or other precipitating factors. To date, there is no cure for herpes viral infections but antivirals can attenuate the symptoms and duration of episodic outbreaks. Prophylactic therapy can suppress recurrences. The first antiviral with selective activity against virus-infected cells is considered to be acyclovir. Our article will highlight the clinical indications of the current generation, valacyclovir, which is a prodrug of acyclovir. We consider valacyclovir as a second-generation antiviral, having taken into account the initial selectivity and safety profile of its progenitor, acyclovir.
authors.affiliation: Solano Research, Davis, CA, USA.
authors.forename: A
authors.initials: A
authors.lastname: Chakrabarty
authors.forename: N J
authors.initials: NJ
authors.lastname: Anderson
authors.forename: R
authors.initials: R
authors.lastname: Beutner
authors.forename: S K
authors.initials: SK
authors.lastname: Tyring
mesh_terms: D000212:Acyclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D006566:Herpesviridae Infections / Q000188:drug therapy*; D006801:Humans; D011355:Prodrugs / Q000627:therapeutic use; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D011355:Prodrugs; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir